Photo: BSIP/Universal Images Group/Getty Images
A company has been created to develop "novel technology" to help treat type 1 diabetes and potentially negate the need for insulin injections.
Islexa, formed after successful pre-clinical studies, will now concentrate on more pre-clinical development, the hope being that trials can take place "in the next few years."
Insulin regulates levels of glucose in our blood.
Type 1 diabetes occurs when the pancreas produces no insulin, while type 2 diabetes refers to when not enough insulin is produced, or when our body's cells "don't react to insulin."
"This is a really exciting technology that has the potential to bring life-changing benefits to these patients," Keith Thompson, CEO of the CGT and Islexa director, said.
"The collaboration has already delivered promising results and the formation of Islexa will accelerate the development of these lab grown islets and ultimately get this potential treatment to thousands of patients," he went on to add.